Isabelle Plantier

Roubaix, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia
Published: April 14, 2026

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

Journal: Blood
Published: May 15, 2025

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia.

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia.

Journal: Blood cancer journal
Published: March 26, 2025

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Journal: Leukemia
Published: October 31, 2024

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 17, 2024

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.

Journal: Blood
Published: December 15, 2023

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.

Journal: Cancers
Published: March 06, 2021

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Journal: Haematologica
Published: October 15, 2020

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Journal: Leukemia
Published: January 24, 2020

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.

Journal: Cancers
Published: July 15, 2019

Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.

Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.

Journal: American journal of hematology
Published: September 20, 2018

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.

Journal: Leukemia
Published: November 20, 2015
Showing 1-12 of 14

Last Updated: 09/26/2026